Another study showed that targeting DDR1 with a humanized monoclonal antibody reversed immune exclusion by increasing T-cell infiltration and significantly increased antitumor efficacy in a mouse model of immunocompetent breast cancer [18]. Here, DDR1 is linked to breast carcinoma.